Vasopressin Synthetic 20 un/mL 1 mL Multi Dose Vial
Vasopressin Injection, USP is a sterile, aqueous solution of synthetic vasopressin (8-L-arginine vasopressin) of the posterior pituitary gland for intramuscular or subcutaneous use. It is substantially free from the oxytocic principle and is standardized to contain 20 pressor units/mL. Each mL contains: Vasopressin 20 units, Sodium Chloride 9 mg, Chlorobutanol 0.5% (as a preservative), Water for Injection q.s. pH (range 2.5 - 4.5) adjusted with Acetic Acid. The structural formula is:
The antidiuretic action of vasopressin is ascribed to increasing reabsorption of water by the renal tubules. Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins. The direct effect on the contractile elements is neither antagonized by adrenergic blocking agents nor prevented by vascular denervation. Following subcutaneous or intramuscular administration of vasopressin injection, the duration of antidiuretic activity is variable but effects are usually maintained for 2-8 hours. The majority of a dose of vasopressin is metabolized and rapidly destroyed in the liver and kidneys. Vasopressin has a plasma half-life of about 10 to 20 minutes. Approximately 5% of a subcutaneous dose of vasopressin is excreted in urine unchanged after four hours.
Indications and Usage
Vasopressin is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus.
Anaphylaxis or hypersensitivity to the drug or its components.
This drug should not be used in patients with vascular disease, especially disease of the coronary arteries, except with extreme caution. In such patients, even small doses may precipitate anginal pain, and with larger doses, the possibility of myocardial infarction should be considered. Vasopressin may produce water intoxication. The early signs of drowsiness, listlessness, and headaches should be recognized to prevent terminal coma and convulsions.
General: Vasopressin should be used cautiously in the presence of epilepsy, migraine, asthma, heart failure or any state in which a rapid addition to extracellular water may produce hazard for an already overburdened system. Chronic nephritis with nitrogen retention contraindicates the use of vasopressin until reasonable nitrogen blood levels have been attained. Information for Patients: Side effects such as blanching of skin, abdominal cramps, and nausea may be reduced by taking 1 or 2 glasses of water at the time of vasopressin administration. These side effects are usually not serious and probably will disappear within a few minutes. Laboratory Tests: Electrocardiograms (ECG) and fluid and electrolyte status determinations are recommended at periodic intervals during therapy. Drug Interactions: 1) The following drugs may potentiate the antidiuretic effect of vasopressin when used concurrently: carbamazepine; chlorpropamide; clofibrate; urea; fludrocortisone; tricyclic antidepressants. 2) The following drugs may decrease the antidiuretic effect of vasopressin when used concurrently: demeclocyline; norepinephrine; lithium; heparin, alcohol. 3) Ganglionic blocking agents may produce a marked increase in sensitivity to the pressor effects of vasopressin. Pregnancy: Teratogenic Effects - Pregnancy Category C. Animal reproduction studies have not been conducted with vasopressin. It is also not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Vasopressin should be given to a pregnant woman only if clearly needed. Labor and Delivery: Doses of vasopressin sufficient for an antidiuretic effect are not likely to produce tonic uterine contractions that could be deleterious to the fetus or threaten the continuation of the pregnancy. Nursing Mothers: Caution should be exercised when vasopressin is administered to a nursing woman.
Local or systemic allergic reactions may occur in hypersensitive individuals. The following side effects have been reported following the administration of vasopressin. Body as a Whole: anaphylaxis (cardiac arrest and/or shock) has been observed shortly after injection of vasopressin. Cardiovascular: cardiac arrest, circumoral pallor, arrhythmias, decreased cardiac output, angina, myocardial ischemia, peripheral vasoconstriction and gangrene. Gastrointestinal: abdominal cramps, nausea, vomiting, passage of gas. Nervous System: tremor, vertigo, “pounding” in head. Respiratory: bronchial constriction. Skin and Appendages: sweating, urticaria, cutaneous gangrene.
Water intoxication may be treated with water restriction and temporary withdrawal of vasopressin until polyuria occurs. Severe water intoxication may require osmotic diuresis with mannitol, hypertonic dextrose, or urea alone or with furosemide.
Dosage and Administration
Vasopressin may be administered intramuscularly or subcutaneously. Ten units of vasopressin (0.5 mL) will usually elicit full physiologic response in adult patients; 5 units will be adequate in many cases. Vasopressin should be given intramuscularly at three- or four-hour intervals as needed. The dosage should be proportionately reduced for children. (For an additional discussion of dosage, consult the sections below.) When determining the dose of vasopressin for a given case, the following should be kept in mind. It is particularly desirable to give a dose not much larger than is just sufficient to elicit the desired physiologic response. Excessive doses may cause undesirable side effects - blanching of the skin, abdominal cramps, nausea - which, though not serious, may be alarming to the patient. Spontaneous recovery from such side effects occurs in a few minutes. It has been found that one or two glasses of water given at the time vasopressin is administered reduce such symptoms. Abdominal Distention: In the average postoperative adult patient, give 5 units (0.25 mL) initially, increase to 10 units (0.5 mL) at subsequent injections if necessary. It is recommended that vasopressin be given intramuscularly and that injections be repeated at three- or four-hour intervals as required. Dosage to be reduced proportionately for children. Vasopressin used in this manner will frequently prevent or relieve postoperative distension. These recommendations apply also to distention complicating pneumonia or other acute toxemias. Abdominal Roentgenography: For the average case, two injections of 10 units each (0.5 mL) are suggested. These should be given two hours and one-half hour, respectively, before films are exposed. Many roentgenologists advise giving an enema prior to the first dose of vasopressin. Diabetes Insipidus: Vasopressin may be given by injection or administered intranasally on cotton pledgets, by nasal spray, or by dropper. The dose by injection is 5 to 10 units (0.25 to 0.5 mL) repeated two or three times daily as needed. When vasopressin is administered intranasally by spray or on pledgets, the dosage and interval between treatments must be determined for each patient. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit.
Vasopressin Injection, USP 20 units/mL is supplied as follows: For intramuscular or subcutaneous use:
NDC 0517-0510-25 10 units per 0.5 mL multiple dose vial Boxes of 25 NDC 0517-1020-25 20 units per 1 mL multiple dose vial Boxes of 25 NDC 0517-0410-10 200 units per 10 mL multiple dose vial Boxes of 10
Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (see USP Controlled Room Temperature).
VASOPRESSIN INJECTION, USP Synthetic Rx Only
AMERICAN REGENT, INC. SHIRLEY, NY 11967
Sample Outer Label
argipressin injection, solution
HUMAN PRESCRIPTION DRUG
Item Code (Source)
Route of Administration
Active Ingredient/Active Moiety
Basis of Strength
20 [USP'U] in 1 mL
1 VIAL, MULTI-DOSE ( VIAL) in 1 BAG
contains a VIAL, MULTI-DOSE
1 mL in 1 VIAL, MULTI-DOSE
This package is contained within the BAG (52584-020-25)
Application Number or Monograph Citation
Marketing Start Date
Marketing End Date
unapproved drug other
Labeler - General Injectables & Vaccines, Inc